The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 998-1003

  Arts, Elke E A ^a   Fransen, Jaap ^a   Broeder, Alfons A Den ^b   Popa, Calin D ^a   Van Riel, Piet L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SINT MAARTENSKLINIEK   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIRHEUMATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; PRIMARY PREVENTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SURVIVAL RATE; ACUTE CORONARY SYNDROME; AGED; ANGINA, STABLE; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CEREBRAL REVASCULARIZATION; HEART MUSCLE REVASCULARIZATION; ISCHEMIC ATTACK, TRANSIENT; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK; SEVERITY OF ILLNESS INDEX; SMOKING; STROKE; TIME; UTILIZATION;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA, STABLE; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CEREBRAL REVASCULARIZATION; COHORT STUDIES; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; NETHERLANDS; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SEVERITY OF ILLNESS INDEX; SMOKING; STROKE; TIME FACTORS;

EID: 84934987105     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204531     Document Type: Article

References (35)

1. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54-8.
2. Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524-9.
3. Del Rincon I, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
5. Rodríguez-Rodríguez L, González-Juanatey C, Palomino-Morales R, et al. TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011;216:125-30.
6. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011;7:399-408.
7. Ahmed HM, Youssef M, Mosaad YM. Antibodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis. Clin Rheumatol 2010;29:1237-43.
8. Del Rincon I, Freeman GL, Haas RW, et al. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005;52:3413-23.
9. Wallberg-Jonsson S, Johansson H, Ohman ML, et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71.
10. Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005;52:2293-99.
11. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis. Arthritis Rheum 2005;52:722-32.
12. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:125-32.
13. Kobayashi H, Giles JT, Polak JF, et al. Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery -specific. JRheumatol2010;37:730-9.
14. Aubry MC, Maradit-Kremers H, Reinalda MS, et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007;34:937-42.
15. Gonzalez-Juanatey C, Llorca J, Testa A, et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003;82:407-13.
16. Karpouzas GA, Malpeso J, Choi TY, et al. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis 2014;73:1797-804.
17. Semb AG, Rollefstad S, Provan SA, et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol 2013;40:359-68.
18. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002;4:R5.
19. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7:R634-43.
20. García-Bermúdez M, González-Juanatey C, López-Mejías R, et al. Study of association of CD40-CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients. PLoS ONE 2012;7:e49214.
21. Toms TE, Panoulas VF, Smith JP, et al. Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:1025-32.
22. Chung CP, Oeser A, Raggi P, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045-53.
23. Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
24. Maradit-Kremers H, Crowson CS, Ballman KV, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402-11.
25. Kerola AM, Kerola T, Kauppi MJ, et al. Cardiovascular comorbidities antedating the diagnosis of rheumatoid arthritis. Ann Rheum Dis 2013;72:1826-9.
26. Kerola AM, Kauppi MJ, Kerola T, et al. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? Ann Rheum Dis 2012;71:1606-15.
27. Statistics Netherlands. Centre for Policy Related Statistics. http://www.cbs.nl/ (accessed Feb 2013).
28. Naz SM, Farragher TM, Bunn DK, et al. The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum 2008;58:985-9.
29. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011;70:8-14.
30. Radovits BJ, Popa-Diaconu DA, Popa C, et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2009;68:1271-76.
31. Provan SA, Semb AG, Hisdal J, et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 2011;70:812-17.
32. Arts EEA, Fransen J, Den Broeder AA, et al. Sustained clinical remission (DAS28<2.6) protects against cardiovascular disease in rheumatoid arthritis patients. 2013 ACR [abstract].
33. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q. 1988;41:155-78.
34. Levi F, Lucchini F, Negri E, et al. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart 2002;88:119-24.
35. Nichols M, Townsend N, Luengo-Fernandez R, et al. European cardiovascular disease statistics. European Heart Network, Brussels, European Society of Cardiology 2012:10-44.